Modality
Vaccine
MOA
CGRPant
Target
JAK2
Pathway
Autophagy
HSIgANSchizophrenia
Development Pipeline
Preclinical
~Oct 2016
→ ~Jan 2018
Phase 1
Apr 2018
→ Feb 2030
Phase 1Current
NCT04002405
639 pts·Schizophrenia
2018-04→2030-02·Recruiting
639 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-02-193.9y awayPh2 Data· Schizophrenia
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
P1/2
Recruit…
Catalysts
Ph2 Data
2030-02-19 · 3.9y away
Schizophrenia
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04002405 | Phase 1/2 | Schizophrenia | Recruiting | 639 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| Sotovorutinib | Pfizer | Approved | Aβ | |
| ABB-3060 | AbbVie | Phase 2 | LAG-3 | |
| GIL-6239 | Gilead Sciences | Phase 2 | TNFα | |
| Tezecilimab | Regeneron | Approved | IL-23 | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| INC-2432 | Incyte | Phase 2 | CD47 | |
| Sematapinarof | Legend Biotech | NDA/BLA | VEGF | |
| Rilufotisoran | Samsung Biologics | NDA/BLA | FXIa | |
| Teravorutinib | Illumina | Phase 2 | JAK2 |